Evidence map›Paper›PMID 35726032›Full record

ReviewEuropean journal of pediatrics2022

Are pro- and/or synbiotics beneficial in Helicobacter pylori eradication therapy in children? A narrative review.

Sari Daelemans, Virginie Deseck, Elvira Ingrid Levy, Yvan Vandenplas

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Adjunctive Synbiotic Therapy forLife (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Frontiers in pharmacology · 2024
    Article
  6. A review for non-antibiotic treatment ofFrontiers in microbiology · 2024
    Review
  7. Therapeutic eradication choices inTherapeutic advances in gastroenterology · 2023
    Review
  8. Comparison of multiple treatment regimens in children withFrontiers in cellular and infection microbiology · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sari DaelemansVrije Universiteit Brussel (VUB), UZ Brussel, KidZ Health Castle, Laarbeeklaan, 101, 1090, Brussels, Belgium.
Virginie DeseckDepartment of Pediatrics, C.H.U. Saint-Pierre, Free University of Brussels, Brussels, Belgium.
Elvira Ingrid LevyVrije Universiteit Brussel (VUB), UZ Brussel, KidZ Health Castle, Laarbeeklaan, 101, 1090, Brussels, Belgium.
Yvan VandenplasVrije Universiteit Brussel (VUB), UZ Brussel, KidZ Health Castle, Laarbeeklaan, 101, 1090, Brussels, Belgium. yvan.vandenplas@uzbrussel.be.ORCID http://orcid.org/0000-0002-1862-8651
Vrije Universiteit Brussel · BEUCLouvain Saint-Louis Brussels · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the effect of pro- and synbiotics in the eradication therapy of Helicobacter pylori (Hp), as well as their effect on adverse effects and therapy compliance in children, a review was performed. We searched for relevant studies published in the English language in PubMed in the last 5 years. Articles were extracted using subject heading and keywords of interest to the topic. There is low-quality evidence that Lactobacillus casei, Bifidobacterium infantis, and Clostridium butyricum (only one RCT for all three) and Saccharomyces boulardii (more than 1 RCT) increase the eradication rate and decrease the adverse effects. Data with synbiotics report only a trend towards a better eradication. Heterogeneity in study designs and outcomes is a major limitation to propose evidence-based recommendations. A reduced incidence of antibiotic-associated diarrhoea is reported. Therapy compliance has been poorly studied.   Conclusion: Due to study heterogeneity, there is very low evidence that some specific probiotics strains increase the eradication rate of Hp when added to standard eradication therapy in children. Whether this is related to immunological effects of the strain or a decrease of adverse effects is not known. More studies, especially comparative trials, are needed before the addition of pro- or synbiotics to Hp eradication treatment can be recommended in daily routine. What is Known: • Eradication treatment of Helicobacter pylori in children has a low success rate and induces frequently adverse effects. • The addition of probiotics might improve eradication and decrease adverse effects, but no paediatric guideline does recommend probiotics as part of the eradication treatment. What is New: • There is low-quality evidence that Lactobacillus casei, Bifidobacteria infantis, and Clostridium butyricum (only one randomized controlled trial (RCT) for all three) and Saccharomyces boulardii (more than 1 RCT) increase the eradication rate and decrease the adverse effects. • Data with synbiotics report only a trend towards a better eradication.

Indexed as

Helicobacter InfectionsHelicobacter pyloriProbioticsSynbioticsChildDrug Therapy, CombinationHumansTreatment OutcomeAntibiotic-associated diarrhoeaBifidobacteriumClostridium butyricumHelicobacter pyloriLactobacillusProbioticSacharomyces boulardiiStreptococcusSynbiotic

Identifiers

PMID35726032
OpenAlexW4283212570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.